Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

SARS antibody test for serosurveillance.

Po-Ren Hsueh1, Chuan-Liang Kao, Chun-Nan Lee

  • 1National Taiwan University College of Medicine, Taipei, Taiwan.

Emerging Infectious Diseases
|October 23, 2004
PubMed
Summary

A new peptide-based enzyme-linked immunosorbent assay (ELISA) aids severe acute respiratory syndrome (SARS) serosurveillance. This safe and automated test identified asymptomatic infections in healthcare workers, revealing undetected disease transmission chains.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

UB-612 pan-SARS-CoV-2 T cell immunity-promoting vaccine protects against COVID-19 moderate-severe disease.

iScience·2024
Same author

The emergence and successful elimination of SARS-CoV-2 dominant strains with increasing epidemic potential in Taiwan's 2021 outbreak.

Heliyon·2023
Same author

Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study.

EBioMedicine·2023
Same author

Toward a pan-SARS-CoV-2 vaccine targeting conserved epitopes on spike and non-spike proteins for potent, broad and durable immune responses.

PLoS pathogens·2023
Same author

Correction: Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy.

Alzheimer's research & therapy·2023
Same author

A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2.

Emerging microbes & infections·2022

Area of Science:

  • Immunology
  • Virology
  • Epidemiology

Background:

  • Severe acute respiratory syndrome (SARS) surveillance is crucial for public health.
  • Previous immunoassays for SARS lacked safety, standardization, and automation.
  • Identifying undetected disease transmission is vital for controlling outbreaks.

Purpose of the Study:

  • To develop and evaluate a peptide-based enzyme-linked immunosorbent assay (ELISA) for SARS retrospective serosurveillance.
  • To assess the sensitivity and specificity of the novel peptide ELISA.
  • To investigate asymptomatic SARS-associated coronavirus infections in healthcare workers.

Main Methods:

  • Epitope mapping using synthetic peptides from SARS-associated coronavirus proteins (spike, membrane, nucleocapsid).

Related Experiment Videos

  • Development of a peptide-based ELISA.
  • Testing specificity with normal blood donors, cross-reactivity samples, and an interference panel.
  • Retrospective serosurvey of healthcare workers in Taiwan.

    • Main Results:

    • The peptide ELISA detected seroconversion by week 2 post-fever onset, with positivity lasting over 100 days.
    • 100% specificity was achieved against various control samples.
    • Asymptomatic seroconversions were identified in healthcare workers in hospitals with nosocomial SARS transmission.

    Conclusions:

    • Peptide-based ELISA is a safe, standardized, and automatable tool for SARS serosurveillance.
    • The assay can detect asymptomatic infections and identify hidden transmission chains.
    • This method is valuable for understanding SARS epidemiology, especially in healthcare settings.